Rain Oncology (NASDAQ:RAIN) Downgraded by Roth Capital to Neutral

Roth Capital lowered shares of Rain Oncology (NASDAQ:RAIN – Get Rating) from a buy rating to a neutral rating in a report published on Tuesday morning, PriceTargets.com reports. A number of other research analysts have also recently weighed in on the company. Oppenheimer cut Rain Oncology from an outperform rating to a market perform rating […]

Related Keywords

United States ,Roth Mkm ,Rain Therapeutics Inc ,Securities Exchange Commission ,Renaissance Technologies ,Morgan Stanley ,Squarepoint Ops ,Rain Oncology Company Profile ,Boxer Capital Llc ,Goldman Sachs Group Inc ,Roth Capital ,Rain Oncology ,Get Rating ,Lifesci Capital ,Oncology Stock Down ,Boxer Capital ,Exchange Commission ,Sachs Group ,Therapeutics Inc ,Rain Oncology Daily ,Nasdaq Rain ,Rain ,Medical ,Downgrade ,